COVID Outcomes in Dermatomyositis
A retrospective study of dermatomyositis (DM) patients with COVID-19, shows that DM patients without comorbidities fair well (with regard to mortality and hospitalisation).
A retrospective study of dermatomyositis (DM) patients with COVID-19, shows that DM patients without comorbidities fair well (with regard to mortality and hospitalisation).
Can we predict the bad outcomes? Like when ITP evolves into SLE; or when psoriasis will develop arthritis; or if Sjogren's will develop lymphoma? Let's dive in and review these journal reports and this past week's news from RheumNow.com.
Dr. Jack Cush discusses declining survival rates in the USA, FDA approvals of new COVID subvariant boosters and other odd and possibly true new research reports from the past week on RheumNow.com.
Today the FDA authorized the updated Omicron subvariant (BA.4 and BA.5) COVID-19 booster shots manufactured by Pfizer and Moderna; with an anticipated ship/start date of early September 2022. The BA.5 subvariant accounts for more than 88% of U.S. infections.
The CDC has published an update to the recommendations from the Advisory Committee on Immunization Practices (ACIP) on the use of seasonal influenza vaccines in the United States for the 2022-23 season.
We've got a lot to discuss this week: psoriasis; fatigue; sleep; sural nerve biopsies; uveitis and SpA; diet and RA; tofacitinib and the ORAL surveillance study; what not to take with mycophenolate - and more. In what order should these items be discussed?
Dr. Jack Cush reviews the news, FDA approvals, journal articles from the past week on RheumNow; plus viewer questions. This week great hopes for vitamin D, the great unknows of CSA and the great big mess that is the gout.
The ACR has posted a new ACR Clinical Practice Guideline Summary providing recommendations on the use of vaccinations for children and adults with rheumatic and musculoskeletal diseases (RMDs).
Editor's note: This podcast originally appeared January 8, 2022.
“One faces the future with one’s past” – Pearl S. Buck
2021 was the year we waited for the other shoe to drop; with the pandemic stone in your shoe, you waited for:
Dr. Jack Cush reviews recent news, regulatory and guideline updates from the past week on RheumNow.com. Studies on methotrexate use, COVID vaccination, Supplements and vitamins, and arthrocentesis despite anticoagulation are discussed.
A cohort study of rheumatoid arthritis (RA) patients evaluated immunogenicity of COVID vaccination with and without holding methotrexate (MTX) for and 2-weeks and showed better immunogenicity, but more RA flares with the second MTX withdrawal.
A study in PNAS of has shown that autoantibodies against type I interferons (IFNs) are strong predictors of death from COVID-19.
Links:
Links:
Links:
Links:
Links:
Anakinra Phase 2/3 study in severe hosp. COVID-19 pts (5/20-3/21) w/ pneumonia & hyperinflammation (incr levels IL-6, ferritin, CRP, LDH). 179 pt Rx w/ ANA or SOC - d15 need for Mech ventilation was 77% ANAK v 86% SoC (NS; RR 0.90; 0.77-1.04) https://t.co/CFcI1qTsU2 https://t.co/wAj4pHN5Dh
Links:
Links: